CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
CD4+CD25+ regulatory T cells (Tregs) are essential negative regulators of immune responses. Here, we examined the signaling properties of human Tregs, using CD4+CD25+ Treg and CD4+CD25– control (Tcont) cell lines generated from cord blood. Treg cell lines were markedly hyporesponsive to stimulation with dendritic cells and with anti-CD3/CD28–coated beads. Hyporesponsiveness was reversed by exogenous interleukin-2 (IL-2). T-cell receptor (TCR)–CD3/CD28–mediated activation of Rap1 and Akt was retained in Tregs, but activation of Ras, mitogenactivated protein kinase 1/2 (MEK1/2), and extracellular signal-regulated kinase 1/2 (Erk1/2) was impaired. Tregs were blocked from cell cycle progression due to decrease of cyclin E and cyclin A and increase of p27kip1 (p27kip cyclin dependent kinase inhibitor). IL-2 induced sustained increase of cyclin E and cyclin A and prevented up-regulation of p27kip1. Tregs had high susceptibility to apoptosis that was reversed by IL-2, which correlated with activation of Erk1/2, up-regulation of Bcl-xL (B-cell CLL/lymphoma 2-like nuclear gene encoding mitochondrial protein, transcript variant 2), and phosphorylation of Bad (Bcl2 antagonist of cell death) at Ser112. Thus, Tregs share biochemical characteristics of anergy, including abortive activation of Ras-MEK-Erk, increased activation of Rap1, and increased expression of p27kip1. In addition, our results indicate that TCR–CD3/CD28–mediated and IL-2 receptor–mediated signals converge at the level of MEK-Erk kinases to regulate Treg survival and expansion and suggest that manipulation of the MEK-Erk axis may represent a novel strategy for Treg expansion for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines
Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K., & Weiss, A. (2001) · Nature Immunology · doi:10.1038/83144 · Cited by 316
Cited by
A Key Role of Leptin in the Control of Regulatory T Cell Proliferation
De Rosa, V., Procaccini, C., Calì, G., Pirozzi, G., Fontana, S., Zappacosta, S., La Cava, A., & Matarese, G. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.011 · Cited by 638
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond
Mohty, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404683 · Cited by 611
González, M. A., Gonzalez‐Rey, E., Rico, L., Büscher, D., & Delgado, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24405 · Cited by 489
Nilsson, J., Boasso, A., Velilla, P. A., Zhang, R., Vaccari, M., Franchini, G., Shearer, G. M., Andersson, J., & Chougnet, C. (2006) · Blood · doi:10.1182/blood-2006-05-021576 · Cited by 338
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis
Flores-Borja, F., Jury, E. C., Mauri, C., & Ehrenstein, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806855105 · Cited by 312
Metadata
- Authors
- Li, L., Godfrey, W. R., Porter, S. B., Ge, Y., June, C. H., Blazar, B. R., & Boussiotis, V. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-11-01
- Volume
- 106
- Issue
- 9
- Pages
- 3068-3073
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2038869692
- Cited by
- 135
- References
- 2
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. https://app.cochat.ai/papers/10.1182/blood-2005-04-1531
- The paper
- Li, L., Godfrey, W. R., Porter, S. B., Ge, Y., June, C. H., Blazar, B. R., & Boussiotis, V. A. (2005). CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. https://doi.org/10.1182/blood-2005-04-1531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.